Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Evaluate the toxicity of cytarabine in patients with refractory systemic lupus
erythematosus.
II. Evaluate objective disease parameters, including serum complement levels, anti-DNA
antibody titers, sedimentation rate, and the systemic lupus activity measure in these
patients.